Experiment 68521
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | ARMSTRONG,WB: KENNEDY,AR: WAN,XS: TAYLOR,TH: NGUYEN,QA: JENSEN,J: THOMPSON,W: LAGERBERG,W: MEYSKENS JR,FL:. (2000). CLINICAL MODULATION OF ORAL LEUKOPLAKIA AND PROTEASE ACTIVITY BY BOWMAN-BIRK INHIBITOR CONCENTRATE IN A PHASE IIA CHEMOPREVENTION TRIAL.. 6(12) |
| Amount utilized | |
| Compound isolated | |
| Disease | A 1-MONTH PHASE IIA CLINICAL TRIAL OF BOWMAN-BIRK INHIBITOR CONCENTRATE (BBIC) IN PATIENTS WITH ORAL LEUKOPLAKIA. BBIC WAS ADMINISTERED TO 32 SUBJECTS WITH ORAL LEUKOPLAKIA FOR 1 MONTH. WE ASSESSED TOXICITY AND CLINICAL AND HISTOLOGICAL RESPONSE OF THE LESIONS, AND ORAL MUCOSAL CELL PORTEASE ACTIVITY (PA) AND SERUM MICRONUTRIENT LEVELS WERE MEASURED. BBIC WAS NONTOXIC IN DOSES UP TO 1066 CHYMOTRYPSIN INHIBITORY UNITS. OVERALL, AT ALL DOSES TESTED, A 24.2% DECREASE IN TOTAL LESION AREA WAS OBSERVED. |
| Dose amount | VAR |
| Number | 1 |
| Qualitative result | INACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |